Citius Oncology, Inc. (NASDAQ: CTOR) reported Phase 1 clinical data for its drug LYMPHIR in combination with pembrolizumab for treating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE